skip to Main Content

Genomics to Match Treatments to Pancreatic Cancer Patients

Newsfeed image, light gray text on dark gray background
Pancreatic cancer is a grim diagnosis, with a five-year survival rate of less than 9 percent. To improve these odds, researchers at UPMC and the University of Pittsburgh School of Medicine sought genetic signatures in the largest study of its kind that could be used to better match drugs to patients and for early detection.

The study involved sifting through the genomes of thousands of tumors, sampled from all over the world. In 17 percent of cases, there was a genetic flag that indicated the tumor should be susceptible to existing chemotherapy drugs. Read more . . . 

Back To Top